Does Cigna Cover Omvoh for Crohn's Disease?

If your gastroenterologist has prescribed Omvoh for Crohn's disease and you have Cigna coverage, you are dealing with one of the newest biologics on the market. Omvoh, the brand name for mirikizumab-mrkz, only received FDA approval for moderately to severely active Crohn's disease in January 2025, more than a year after its 2023 approval for ulcerative colitis. Because the Crohn's indication is so recent, plan-specific guidance is thin, and many patients cannot find a clear answer to a simple question. The short version is that Cigna does cover Omvoh for Crohn's disease, but coverage runs through prior authorization and step therapy, and approval depends on documentation. This article maps how that process works.

How Cigna Handles Pharmacy and Specialty Biologics

Cigna does not administer its pharmacy benefit directly. It manages prescription drugs through Express Scripts, and routes home delivery through Express Scripts Pharmacy. Specialty biologics like Omvoh are dispensed through Accredo, the Cigna Healthcare specialty pharmacy, where specialty-trained pharmacists and nurses fill and ship the medication. This structure matters because Omvoh has two components. Induction uses an intravenous infusion that a provider administers, while maintenance uses a subcutaneous injection that often ships to your home. Depending on your plan, the infusion may bill under the medical benefit and the injections under the pharmacy benefit, so two separate authorizations can apply. Knowing which benefit covers each piece helps you anticipate where a delay might occur.

What Omvoh Is and Why It Sits Later in Line

Omvoh is an interleukin-23 antagonist that targets the IL-23p19 protein, a driver of intestinal inflammation. For Crohn's disease, the label specifies a 900 mg intravenous induction dose at weeks 0, 4, and 8, followed by 300 mg subcutaneously at week 12 and every 4 weeks thereafter. Its approval rests on the phase 3 VIVID-1 trial, a treat-through study in patients with moderately to severely active Crohn's disease who had an inadequate response to standard therapies. In that trial, 53% of mirikizumab-treated patients achieved clinical remission at one year versus 36% on placebo, and 46% reached endoscopic response versus 23%. As the newest entrant, Omvoh is typically positioned as a later-line agent, which shapes how Cigna gates it.

Prior Authorization and Step Therapy

Coverage of Omvoh is not automatic. Cigna's published coverage policies require prior authorization for both formulations. For the infusion, the Omvoh intravenous policy approves three induction doses when the patient is an adult with moderate to severe Crohn's disease and meets the criteria, and it notes that preferred products must be used before Omvoh is approved. For the injection, the Omvoh subcutaneous policy approves initial therapy for six months and continuation for one year once a patient has been established on treatment. In practice, a newly approved agent like Omvoh is usually gated behind documented failure of preferred agents, which can include tumor necrosis factor inhibitors and other established biologics. Because policies and preferred-product lists change and vary by plan, confirm the current criteria in your own plan documents before assuming what applies to you.

Building the Medical-Necessity Case

Because Omvoh sits later in the treatment sequence, the strongest prior authorization request documents why earlier therapies were inadequate. Cigna's coverage policies reference society guidance, including the American College of Gastroenterology guideline on managing Crohn's disease in adults, which informs how advanced therapies are sequenced. A complete request typically captures three things.

• The biologics or conventional therapies you have already tried, with dates and outcomes

• The reason each was stopped, such as loss of response, intolerance, or contraindication

• Objective measures of active disease, such as endoscopy or biomarker results

Keeping a clear treatment history makes the medical-necessity narrative concrete rather than vague, which is what reviewers look for. The more specific the record of prior failures, the easier it is for a reviewer to see that Omvoh is an appropriate next step under the step-therapy criteria.

What to Do If Cigna Denies Coverage

A denial at first pass is common with step therapy, and it is rarely the end of the road. Read the denial letter closely, because it states the specific reason, whether that is a missing preferred-product trial, incomplete documentation, or a benefit question. If the denial is based on step therapy and you have already failed the preferred agents, you can request a formal appeal and ask your prescriber to submit a letter of medical necessity addressing each criterion in the Cigna Omvoh coverage policy. A peer-to-peer review, where your gastroenterologist speaks directly with Cigna's reviewing physician, can also resolve cases that hinge on clinical judgment. Throughout the process, verify your specific plan rather than relying on general policy summaries, since self-funded employer plans can apply different rules.

Conclusion

Cigna covers Omvoh for Crohn's disease, but the path runs through prior authorization, a preferred-product step-therapy gate, and benefit logistics split between Express Scripts and Accredo. Because the Crohn's indication arrived only in 2025, you are unlikely to find detailed plan-specific guidance, which makes documentation your strongest asset. A thorough record of prior biologic trials and outcomes, paired with objective evidence of active disease, gives your prior authorization the best chance of clearing the step-therapy requirement. If the first request is denied, an appeal supported by a detailed letter of medical necessity and a peer-to-peer review often reverses the outcome. The criteria can change over time, so confirm the current rules in your own plan documents and coverage policy before you begin.